<DOC>
	<DOCNO>NCT02056808</DOCNO>
	<brief_summary>The purpose study determine whether increase dos SMT C1100 safe , well tolerate achieve appropriate blood level patient Duchenne Muscular Dystrophy ( DMD ) .</brief_summary>
	<brief_title>A Phase 1b Study SMT C1100 Subjects With Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>Primary Objective : To determine safety tolerability single multiple oral dos SMT C1100 patient Duchenne Muscular Dystrophy ( DMD ) . Secondary Objectives : To determine single multiple oral dose pharmacokinetics SMT C1100 metabolites patient DMD .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Patients male ethnic origin genetic diagnosis DMD . Children 5 11 year age . A parent/legal guardian must date sign write consent behalf patient , accord International Conference Harmonisation ( ICH ) local regulation . This person must understand content consent , requirement study opportunity review question medically trained member site study team . The patient willing give verbal write age appropriate assent participate . For safety reason , patient 's parent/legal guardian must good understanding English language , language consent/assent form write , understand requirement report adverse event Investigator . Enrollment participation therapeutic clinical trial within prior 3 month 5 time halflife ( whichever longer ) . Initiation change ( dose modification body weight ) systemic corticosteroid therapy within 2 month prior start dose administration discontinuation corticosteroid within 30 day prior start dose administration . Known hypersensitivity excipients study drug previous history drug allergy . Use follow therapy prohibit study least 5 halflives prior start dose administration : Inducers cytochrome P450 CYP1A2 ( eg , carbamazepine , phenytoin , primidone , rifampin , omeprazole , barbiturate ) , moderate strong inhibitor CYP1A2 ( e.g. , fluvoxamine , ciprofloxacin , enoxacin , mexiletine ; propafenone , zileuton ) . Substrates CYP1A2 narrow therapeutic window ( e.g. , tacrine , theophylline , methadone , mexiletine ) . Nicotine , include exposure daily passive smoking minimize cytochrome P450 CYP 1A induction . Chargrilled food , cruciferous vegetable , caffeine , tea , xanthine contain food , drink prohibit 36 hour prior checkin final discharge study . Herbal supplement homeopathic preparation ( unless approve medical monitor ) . Need mechanical ventilation . Non ambulatory . Any clinically significant acute illness within 4 week start dose administration . Any comorbidity , opinion Investigator , increase risk participate study . Symptomatic cardiomyopathy opinion Investigator prohibit participation study . Abnormality 12lead ECG , opinion Investigator , increase risk participate study . Any clinically significant medical condition , DMD opinion Investigator may increase risk participate study interfere interpretation safety efficacy evaluation ( e.g. , concomitant illness , psychiatric condition behavioral disorder ) . Exposure daily passive smoking ( include parent/legal guardian , sibling ) minimize environmental factor cause cytochrome P450 CYP 1A induction . For information SMT C1100 metabolize cytochrome P450 CYP 1A . Excessive exercise ( Investigator opinion ) .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>